Cargando…

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay

BACKGROUND: Fostemsavir is a prodrug of a first-in-class HIV-1 attachment inhibitor, temsavir, that binds to gp120 and blocks attachment to the host-cell CD4 receptor, preventing entry and infection of the target cell. Previous studies using a limited number of clinical isolates showed that there wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gartland, Margaret, Zhou, Nannan, Stewart, Eugene, Pierce, Amy, Clark, Andrew, Ackerman, Peter, Llamoso, Cyril, Lataillade, Max, Krystal, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879148/ https://www.ncbi.nlm.nih.gov/pubmed/33241285 http://dx.doi.org/10.1093/jac/dkaa474

Ejemplares similares

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
por: Lagishetty, Chakradhar, et al.
Publicado: (2020)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Fostemsavir for HIV-1 infection
Publicado: (2022)

365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
por: Dyson, Alftan, et al.
Publicado: (2023)

834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
por: Chabria, Shiven, et al.
Publicado: (2021)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

Pheno 2019
Publicado: (2019)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

Pheno 2005 Symposium
Publicado: (2005)

PHENO 2001 Symposium
Publicado: (2001)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
por: Wang, Tao, et al.
Publicado: (2021)

Future Perspectives at HL-LHC Prospects for Pheno26, Pheno31, and beyond
por: Jeanty, Laura
Publicado: (2021)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

Enhancing Phenotype Recognition in Clinical Notes Using Large Language Models: PhenoBCBERT and PhenoGPT
por: Yang, Jingye, et al.
Publicado: (2023)

Phenomenology 2017 Symposium (PHENO 2017)
Publicado: (2017)

Phenomenology 2022 Symposium (PHENO 2022)
Publicado: (2022)

Pheno- and Genotyping of Hopanoid Production in Acidobacteria
por: Damsté, Jaap S. Sinninghe, et al.
Publicado: (2017)

PhenoFly Planning Tool: flight planning for high-resolution optical remote sensing with unmanned areal systems
por: Roth, Lukas, et al.
Publicado: (2018)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

Green-adapted spectrophotometric determination of fostemsavir based on selective bromophenol blue extraction; reduction of hazardous consumption using computational calculations
por: Batubara, Afnan S., et al.
Publicado: (2023)

International Symposium on Recent Developments in Phenomenology : Pheno '97
por: Collective
Publicado: (1997)

International Symposium on Recent Developments in Phenomenology : Pheno '96
por: Collective
Publicado: (1997)

Physics at the LHC presented at the StringPheno2009 conference
por: Przysiezniak, H
Publicado: (2009)

Visualizing genomic information across chromosomes with PhenoGram
por: Wolfe, Daniel, et al.
Publicado: (2013)

PhenoImageShare: an image annotation and query infrastructure
por: Adebayo, Solomon, et al.
Publicado: (2016)

Visualizing cellular imaging data using PhenoPlot
por: Sailem, Heba Z., et al.
Publicado: (2015)

Testing Hopkins’ Bioclimatic Law with PhenoCam data
por: Richardson, Andrew D., et al.
Publicado: (2019)

The Pheno- and Genotypic Characterization of Porcine Escherichia coli Isolates
por: Bernreiter-Hofer, Tanja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fao1kjfs8dcqg419d00e0tmmnd